| Title: |
Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease |
| Authors: |
Allanore, Yannick; Khanna, Dinesh; Smith, Vanessa; Aringer, Martin; Hoffmann-Vold, Anna-Maria; Kuwana, Masataka; Merkel, Peter A; Stock, Christian; Sambevski, Steven; Denton, Christopher P; Bergna, M; Casado, G; Mannucci Walter, P; Proudman, S; Stevens, W; Thakkar, V; Troy, L; Loeffler-Ragg, J; Olschewski, H; André, B; Bondue, B; Houssiau, F; Smith, V; Wuyts, W; Azevedo, V; Johnson, S; Keystone, E; Khalidi, N; Levesque, M; Rozas, R Maturana; Silva Orellana, A; Huang, C; Li, J; Jiang, Z; Liu, Y; Xiao, W; Xu, J; Zeng, X; Zheng, Y; Zou, H; Becvar, R; Madsen, H; Søndergaard, K; Kilpeläinen, M; Myllärniemi, M; Agard, C; Allanore, Y; Bourdin, A; Cottin, V; Crestani, B; Diot, E; Dominique, S; Hachulla, E; Jouneau, S; Leroy, S; Nunes, H; Prevot, G; Wallaert, B; Wemeau, L; Aringer, M; Bewig, B; Blaas, S; Distler, J; Ehrchen, J; Ewert, R; Gläser, S; Henes, J; Hunzelmann, N; König, R; Kötter, I; Kreuter, M; Prasse, A; Schulze-Koops, H; Sfikakis, P; Vlachoyiannopoulos, P; Losonczy, G; Behera, D; Gayathri Devi, H J; Kadel, J; Kawedia, M; Kumar, D; Kumar, U; Lokhande, R; Malpani, A; Mohan, M; Nalawade, A; Parakh, U; Swarnakar, R; Shobha, V; Thangakunam, B; Udwadia, Z; Henry, M; O'Reilly, K; Balbir-Gurman, A; Kramer, M; Litinsky, I; Rosner, I; Cutolo, M; Gabrielli, A; Iaccarino, L; Pesci, A; Riccieri, V; Vettori, S; Funakubo, Y; Inoue, Y; Kawakami, A; Kawaguchi, Y; Kawamura, T; Kondoh, Y; Kuwana, M; Nanki, T; Nishioka, Y; Nozawa, K; Ogura, T; Okamoto, M; Sano, H; Sasai, R; Sasaki, N; Suda, T; Takahashi, H; Takeuchi, T; Makino, S; Tanaka, S; Yamasaki, Y; Ch'ng, S S; Cheah, C; Kan, S; Raja Mohamed, R B; Selman, M; de Vries-Bouwstra, J K; van den Toorn, L; Vonk, M; Voskuyl, A E; Hoffmann-Vold, A M; Seip, M; Dankiewicz-Fares, I; Olesiejuk, R; Pulka, G; Szepietowski, J; Alves, J; Bernardes, M; Cordeiro, A; Costa, J; Neves, S; Salvador, M J; Alegre Sancho, J; Carreira Delgado, P; Castellví Barranco, I; Cifrián Martínez, J; Guillén del Castillo, A; Ovalles, J G; López-Longo, F J; Rivera Gallego, A; Freire Dapena, M C; Román Ivorra, J A; Ekwall, A-K H; Maurer, B; Mihai, C M; Müller, R; Mahakkanukrauh, A; Nantiruj, K; Siripaitoon, B; Denton, C P; Herrick, A; Madhok, R; Maher, T M; West, A; Antin-Ozerkis, D; Bascom, R; Criner, G; Csuka, M E; Dematte D'Amico, J; Ettinger, N; Fischer, A; Gerbino, A; Gerke, A; Glassberg, M; Glazer, C; Golden, J; Gripaldo, R; Gupta, N; Hamblin, M; Highland, K; Ho, L; Huggins, J T; Hummers, L; Jones, L; Kahaleh, M; Khanna, D; Kim, H; Lancaster, L H; Luckhardt, T; Mayes, M; Mendoza Ballesteros, F; Mooney, J; Mohabir, P; Morrissey, B; Moua, T; Padilla, M; Patel, N; Perez, R; Roman, J; Rossman, M; Russell, T; Saketkoo, L; Shah, A; Shlobin, O; Scholand, M B; Simms, R; Spiera, R; Steen, V; Veeraraghavan, S; Weigt, S; SENSCIS Trial Investigators, missing |
| Source: |
RHEUMATOLOGY ; ISSN: 1462-0324 ; ISSN: 1462-0332 |
| Publication Year: |
2024 |
| Collection: |
Ghent University Academic Bibliography |
| Subject Terms: |
Medicine and Health Sciences; Pharmacology (medical); Rheumatology; systemic; scleroderma; pulmonary function tests; pulmonary fibrosis; antifibrotic agents |
| Description: |
Objectives To investigate the course of interstitial lung disease (ILD) and the effects of nintedanib in patients with limited cutaneous systemic sclerosis (lcSSc).Methods In the SENSCIS trial, patients with SSc-ILD were randomized to receive nintedanib or placebo. Patients who completed the SENSCIS trial were eligible to enter SENSCIS-ON, in which all patients received open-label nintedanib.Results Among 277 patients with lcSSc treated in the SENSCIS trial, the rate (s.e.) of decline in forced vital capacity (FVC; ml/year) over 52 weeks was -74.5 (19.2) in the placebo group and -49.1 (19.8) in the nintedanib group (difference: 25.3 [95% CI -28.9, 79.6]). Among 249 patients with data at week 52, mean (s.e.) change in FVC at week 52 was -86.4 (21.1) ml in the placebo group and -39.1 (22.2) ml in the nintedanib group. Among 183 patients with lcSSc who participated in SENSCIS-ON and had data at week 52, mean (s.e.) change in FVC from baseline to week 52 of SENSCIS-ON was -41.5 (24.0) ml in patients who took placebo in the SENSCIS trial and initiated nintedanib in SENSCIS-ON and -45.1 (19.1) ml in patients who took nintedanib in the SENSCIS trial and continued it in SENSCIS-ON.Conclusion Patients with lcSSc may develop progressive fibrosing ILD. By targeting pulmonary fibrosis, nintedanib slows decline in lung function in patients with lcSSc and ILD. |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| Relation: |
https://biblio.ugent.be/publication/01HJ93Y8WR3PFQTQ5012QFQHCA; https://doi.org/10.1093/rheumatology/kead280; https://biblio.ugent.be/publication/01HJ93Y8WR3PFQTQ5012QFQHCA/file/01HJ940GFB4YQW7HFB6Z6TDKZY |
| DOI: |
10.1093/rheumatology/kead280 |
| Availability: |
https://biblio.ugent.be/publication/01HJ93Y8WR3PFQTQ5012QFQHCA; https://hdl.handle.net/1854/LU-01HJ93Y8WR3PFQTQ5012QFQHCA; https://doi.org/10.1093/rheumatology/kead280; https://biblio.ugent.be/publication/01HJ93Y8WR3PFQTQ5012QFQHCA/file/01HJ940GFB4YQW7HFB6Z6TDKZY |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.36FB4DFE |
| Database: |
BASE |